EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhancing anticancer activity of macrophages through rational drug combinations

Gordon B Mills, Marilyne Labrie

Journal of Clinical Investigation · 01.05.2024 · 134 (9)

DOI: 10.1172/jci180512 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.05.2024. Verfasst von Gordon B Mills und 1 weiteren Autor:innen. Beteiligte Einrichtung: Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Tumor-Associated Macrophages, CD47 Antigen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting tumor-associated macrophages (TAMs) is an emerging approach being tested in multiple clinical trials. TAMs, depending on their differentiation state, can exhibit pro- or antitumorigenic functions. For example, the M2-like phenotype represents a protumoral state that can stimulate tumor growth, angiogenesis, metastasis, therapy resistance, and immune evasion by expressing immune checkpoint proteins. In this issue of the JCI , Vaccaro and colleagues utilized an innovative drug screen approach to demonstrate that targeting driver oncogenic signaling pathways concurrently with anti-CD47 sensitizes tumor cells, causing them to undergo macrophage-induced phagocytosis. The combination treatment altered expression of molecules on the tumor cells that typically limit phagocytosis. It also reprogrammed macrophages to an M1-like antitumor state. Moreover, the approach was generalizable to tumor cells with different oncogenic pathways, opening the door to precision oncology–based rationale combination therapies that have the potential to improve outcomes for patients with oncogene-driven lung cancers and likely other cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor-Associated MacrophagesCD47 AntigenHumansAnimalsPhagocytosisNeoplasmsMacrophagesAntineoplastic Combined Chemotherapy ProtocolsLung Neoplasms

Substanzen

CD47 AntigenCD47 protein, human

Autor:innen und Institutionen

  • Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
  • Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke (CRCHUS), Sherbrooke, Quebec, Canada.
  • Institut de Recherche sur le Cancer de l'Université de Sherbrooke (IRCUS), Sherbrooke, Quebec, Canada.

Förderung

  • NCI NIH HHS

Zitieren

APA

Mills, G. B., & Labrie, M. (2024). Enhancing anticancer activity of macrophages through rational drug combinations. Journal of Clinical Investigation, 134(9). https://doi.org/10.1172/jci180512

Vancouver

Mills GB, Labrie M. Enhancing anticancer activity of macrophages through rational drug combinations. Journal of Clinical Investigation. 2024;134(9). doi:10.1172/jci180512

BibTeX
@article{Mills2024,
  author = {Mills, Gordon B and Labrie, Marilyne},
  title = {Enhancing anticancer activity of macrophages through rational drug combinations},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {9},
  doi = {10.1172/jci180512}
}
Kostenlos starten →